Literature DB >> 15049516

Riluzole enhances glutamate uptake in rat astrocyte cultures.

Marcos Emílio dos Santos Frizzo1, Leonara Patrícia Dall'Onder, Karina Borges Dalcin, Diogo Onofre Souza.   

Abstract

1. Riluzole is used for the treatment of amyotrophic lateral sclerosis and reported to have neuroprotective effects in animal models of Parkinson's disease, Huntington's disease, and brain ischemia. The neuroprotective action of riluzole has been attributed to its ability to inhibit glutamate release (A. Doble, Neurology 47(4):233S-241S, 1996). 2. The effect of riluzole on L-[2,3-3H] glutamate uptake was investigated in rat cortical astrocyte cultures. 3. Riluzole showed a biphasic concentration-dependent effect on basal glutamate uptake. At low concentrations (1 and 10 microM) riluzole significantly increased glutamate uptake, whereas from 100 microM promoted a slight reduction. 4. Considering the large range of glutamate levels in the synaptic cleft, we studied the 1 microM riluzole effect on uptake of glutamate at different concentrations (1-1000 microM). Riluzole was more effective at low glutamate concentrations (10 microM), enhancing the basal glutamate uptake up to 42%. 5. The action of riluzole on astrocytic glutamate uptake could be an additional mechanism to its neuroprotective role, perhaps suggesting a modulatory action on glutamatergic system involving glutamate clearance from synaptic cleft.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15049516     DOI: 10.1023/b:cemn.0000012717.37839.07

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  11 in total

1.  Activation of glutamate uptake by guanosine in primary astrocyte cultures.

Authors:  M E Frizzo; D R Lara; K C Dahm; A S Prokopiuk; R A Swanson; D O Souza
Journal:  Neuroreport       Date:  2001-03-26       Impact factor: 1.837

Review 2.  Glutamate transporters in neurologic disease.

Authors:  N J Maragakis; J D Rothstein
Journal:  Arch Neurol       Date:  2001-03

3.  Intoxication with riluzole in Huntington's disease.

Authors:  T Bodner; C Jenner; T Benke; A Ober; K Seppi; W W Fleischhacker
Journal:  Neurology       Date:  2001-09-25       Impact factor: 9.910

Review 4.  Astrocyte glutamate transport: review of properties, regulation, and physiological functions.

Authors:  C M Anderson; R A Swanson
Journal:  Glia       Date:  2000-10       Impact factor: 7.452

5.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

6.  Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis.

Authors:  John Dunlop; H Beal McIlvain; Yijin She; David S Howland
Journal:  J Neurosci       Date:  2003-03-01       Impact factor: 6.167

Review 7.  Glutamate uptake.

Authors:  N C Danbolt
Journal:  Prog Neurobiol       Date:  2001-09       Impact factor: 11.685

8.  Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamate- and GABA-mediated neurotransmission and of ion channels.

Authors:  F Peña; R Tapia
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

9.  Epidermal growth factor receptor agonists increase expression of glutamate transporter GLT-1 in astrocytes through pathways dependent on phosphatidylinositol 3-kinase and transcription factor NF-kappaB.

Authors:  O Zelenaia; B D Schlag; G E Gochenauer; R Ganel; W Song; J S Beesley; J B Grinspan; J D Rothstein; M B Robinson
Journal:  Mol Pharmacol       Date:  2000-04       Impact factor: 4.436

Review 10.  The pharmacology and mechanism of action of riluzole.

Authors:  A Doble
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

View more
  84 in total

Review 1.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

2.  Glial and glutamatergic markers in depression, alcoholism, and their comorbidity.

Authors:  José Javier Miguel-Hidalgo; Robert Waltzer; Angela A Whittom; Mark C Austin; Grazyna Rajkowska; Craig A Stockmeier
Journal:  J Affect Disord       Date:  2010-06-26       Impact factor: 4.839

Review 3.  Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach.

Authors:  Rodrigo Machado-Vieira; Marcio G Soeiro-De-Souza; Erica M Richards; Antonio L Teixeira; Carlos A Zarate
Journal:  World J Biol Psychiatry       Date:  2013-09-02       Impact factor: 4.132

4.  Neuroprotective agents: is effective on toxicity in glial cells?

Authors:  Taner Dagci; Ozlem Yilmaz; Dilek Taskiran; Gonul Peker
Journal:  Cell Mol Neurobiol       Date:  2006-06-07       Impact factor: 5.046

5.  Neuroprotective drug riluzole amplifies the heat shock factor 1 (HSF1)- and glutamate transporter 1 (GLT1)-dependent cytoprotective mechanisms for neuronal survival.

Authors:  Alice Y C Liu; Rohan Mathur; Newton Mei; Christopher G Langhammer; Bruce Babiarz; Bonnie L Firestein
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

6.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

7.  Glutamate transporter type 3 participates in maintaining morphine-induced conditioned place preference.

Authors:  Li Wan; Jiangjiang Bi; Jun Li; Zhiyi Zuo
Journal:  Neuroscience       Date:  2017-01-01       Impact factor: 3.590

8.  Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models.

Authors:  Holly C Hunsberger; Sharay E Setti; Ryan T Heslin; Jorge E Quintero; Greg A Gerhardt; Miranda N Reed
Journal:  J Vis Exp       Date:  2017-05-03       Impact factor: 1.355

9.  Activation of glutamate transporters in the locus coeruleus paradoxically activates descending inhibition in rats.

Authors:  Ken-ichiro Hayashida; Renee A Parker; James C Eisenach
Journal:  Brain Res       Date:  2010-01-06       Impact factor: 3.252

Review 10.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.